Cybin Inc

Cybin Inc. is a clinical-stage neuropsychiatry company developing psychedelic-based therapeutics for mental health conditions. Its pipeline includes CYB003, a deuterated psilocybin analog in phase 3 trials for major depressive disorder (MDD), and CYB004, a deuterated N,N-dimethyltryptamine (DMT) in phase 2 trials for generalized anxiety disorder. It also develops SPL028, an injectable deuterated DMT that completed phase 1 intramuscular and intravenous trials, SPL026 for MDD, and CYB005, a preclinical phenethylamine derivative for central nervous system conditions, alongside a research pipeline of investigational psychedelic-based compounds. The company has a strategic partnership with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 as an adjunctive treatment for MDD, and is headquartered in Toronto, Canada.